Publication date: Jul 10, 2019
Dr Gerald Batist speaks to ecancer at the WIN 2019 Symposium in Paris about a precision medicine approach to therapeutic resistance using KEAP1 somatic mutations to target patients to correct protein-protein interaction disrupted by this mutation.
He explains that often cancer patients will relapse and second and third lines of therapy become unsuccessful due to resistance.
Dr Batist explains that using molecular modelling they have found a drug that can lower resistance and sensitise tumours to chemotherapies and immunotherapies.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
- Keynote Presentation: The Impact of Patient-to-Patient Variability on Combination Cancer..
- A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies.